Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global epidemiology of haemoglobin disorders and derived service indicators.Bull World Health Organ. 2008; 86: 480-487
- World distribution, population genetics, and health burden of the hemoglobinopathies.Cold Spring Harb Perspect Med. 2012; 2: a011692
- Thalassemia: an overview of 50 years of clinical research.Hematol Oncol Clin North Am. 2010; 24: 1005-1020
- beta-Thalassemias.N Engl J Med. 2021; 384: 727-743
- MOLECULAR MEDICINE: Found in Translation.Med (N Y). 2021; 2: 122-136
- The switch from fetal to adult hemoglobin.Cold Spring Harb Perspect Med. 2013; 3: a011643
- Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.Br J Haematol. 2018; 180: 630-643
- Sickle cell disease.Nat Rev Dis Primers. 2018; 4: 18010
- Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia.Blood. 1963; 21: 21-32
- Absorption spectra of inclusion bodies in beta-thalassemia.Blood. 1965; 25: 105-109
- The significance of the paucity of sickle cells in newborn Negro infants.Am J Med Sci. 1948; 215: 419-423
- Heterocellular hereditary persistence of fetal haemoglobin and homozygous sickle-cell disease.Lancet. 9 1977; 1: 795-796
- Haemoglobin E beta thalassaemia in Sri Lanka.Lancet. 2005; 366: 1467-1470
- A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E.Hum Genet. 2010; 127: 303-314
- Amelioration of Sardinian beta0 thalassemia by genetic modifiers.Blood. 2009; 114: 3935-3937
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia.Proc Natl Acad Sci U S A. 2008; 105: 1620-1625
- Fetal hemoglobin levels and morbidity in untransfused patients with beta-thalassemia intermedia.Blood. 2012; 119: 364-367
- Pain in sickle cell disease. Rates and risk factors.N Engl J Med. 1991; 325: 11-16
- Mortality in sickle cell disease. Life expectancy and risk factors for early death.N Engl J Med. 1994; 330: 1639-1644
- The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.Blood. 1994; 84: 643-649
- DNA methylation in the human gamma delta beta-globin locus in erythroid and nonerythroid tissues.Cell. 1980; 19: 947-958
- 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.N Engl J Med. 1982; 307: 1469-1475
- 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia.Blood. 1983; 62: 370-380
- Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia.Blood. 2013; 121 ([quiz: 2372]): 2199-2212
- Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea.N Engl J Med. 1984; 310: 869-873
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.J Clin Invest. 1984; 74: 652-656
- Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.N Engl J Med. 1995; 332: 1317-1322
- Delay in the fetal globin switch in infants of diabetic mothers.N Engl J Med. 1985; 312: 334-338
- Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers.Pediatrics. 1985; 75: 1143-1147
- A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.N Engl J Med. 1993; 328: 81-86
- Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.N Engl J Med. 1995; 332: 1606-1610
- Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin.Blood. 2007; 110: 3391-3397
- Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.Proc Natl Acad Sci U S A. 2010; 107: 12617-12622
- Synergistic silencing of alpha-globin and induction of gamma-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for beta-thalassaemia.Sci Rep. 2019; 9: 11649
- beta-Thalassemia: evolving treatment options beyond transfusion and iron chelation.Hematol Am Soc Hematol Educ Program. 2021; 2021: 600-606
- A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15.Nat Genet. 2007; 39: 1197-1199
- Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults.Proc Natl Acad Sci U S A. 2007; 104: 11346-11351
- DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease.Proc Natl Acad Sci U S A. 2008; 105: 11869-11874
- Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation.Nat Genet. 2010; 42: 1049-1051
- Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A.Science. 2008; 322: 1839-1842
- Control of human hemoglobin switching by LIN28B-mediated regulation of BCL11A translation.Nat Genet. 2020; 52: 138-145
- Developmental and species-divergent globin switching are driven by BCL11A.Nature. 2009; 460: 1093-1097
- An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.Science. 2013; 342: 253-257
- BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.Nature. 2015; 527: 192-197
- BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.J Clin Invest. 2015; 125: 2363-2368
- BCL11A Haploinsufficiency Causes an Intellectual Disability Syndrome and Dysregulates Transcription.Am J Hum Genet. 2016; 99: 253-274
- Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing.Plos Genet. 2021; 17: e1009835
- Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing.Science. 2011; 334: 993-996
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia.N Engl J Med. 21 2021; 384: 252-260
- Posttranscriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.N Engl J Med. 2021; 384: 205-215
- CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia.Nat Med. 2022; 28: 1573-1580
- Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.Science. 2016; 351: 285-289
- A unified model of human hemoglobin switching through single-cell genome editing.Nat Commun. 2021; 12: 4991
- Structural basis for human ZBTB7A action at the fetal globin promoter.Cell Rep. 2021; 36: 109759
- Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.Nat Genet. 2018; 50: 498-503
- De novo ZBTB7A variant in a patient with macrocephaly, intellectual disability, and sleep apnea: implications for the phenotypic development in 19p13.3 microdeletions.J Hum Genet. 2020; 65: 181-186
- Heterozygous variants in ZBTB7A cause a neurodevelopmental disorder associated with symptomatic overgrowth of pharyngeal lymphoid tissue, macrocephaly, and elevated fetal hemoglobin.Am J Med Genet A. 2022; 188: 272-282
- 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment.Blood. 2015; 126: 89-93
- Identification of novel BCL11A variants in patients with epileptic encephalopathy: Expanding the phenotypic spectrum.Clin Genet. 2018; 93: 368-373
- Molecular analysis of the erythroid phenotype of a patient with BCL11A haploinsufficiency.Blood Adv. 2021; 5: 2339-2349
- Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch.Cell. 2018; 173: 430-442 e17
- Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.Genes Dev. 2010; 24: 783-798
- Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A.Proc Natl Acad Sci U S A. 2013; 110: 6518-6523
- Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells.PLoS One. 2013; 8: e59890
- RNA-binding proteins in human genetic disease.Nat Rev Genet. 2021; 22: 185-198
- LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.Blood. 2013; 122: 1034-1041
- IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts.Proc Natl Acad Sci U S A. 2017; 114: E5664-E5672https://doi.org/10.1073/pnas.160955211
- Dual function NFI factors control fetal hemoglobin silencing in adult erythroid cells.Nat Genet. 2022; 54: 874-884
- HIC2 controls developmental hemoglobin switching by repressing BCL11A transcription.Nat Genet. 2022; 54: 1417-1426
- Rational targeting of a NuRD subcomplex guided by comprehensive in situ mutagenesis.Nat Genet. 2019; 51: 1149-1159
- ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression.Mol Cell. 2021; 81: 239-254 e8
- ZNF410 represses fetal globin by singular control of CHD4.Nat Genet. 2021; 53: 719-728
- Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat beta-hemoglobinopathies.Mol Ther. 2022; 30: 2693-2708
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
